ARS Pharmaceuticals, Inc.

SPRY · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income$7,998-$54,365-$34,682-$20,243
Dep. & Amort.-$7,175$73$319$213
Deferred Tax$0$0$0$0
Stock-Based Comp.$14,534$9,235$5,843$2,829
Change in WC-$1,809-$7,331-$12,754-$356
Other Non-Cash$0-$6,878$1,196-$4
Operating Cash Flow$13,548-$59,266-$40,078-$17,561
Investing Activities
PP&E Inv.-$563-$175-$199-$55
Net Acquisitions$0$0$0$0
Inv. Purchases-$356,038-$272,005$0$0
Inv. Sales/Matur.$258,000$185,000$0$0
Other Inv. Act.-$7,500$0$0$0
Investing Cash Flow-$106,101-$87,180-$199-$55
Financing Activities
Debt Repay.$69,383$0-$8,681-$1,817
Stock Issued$3,016$6,899$570$0
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$0$0$198,843$54,975
Financing Cash Flow$72,399$6,899$190,732$53,158
Forex Effect$0$0$0$0
Net Chg. in Cash-$20,154-$139,547$150,455$35,542
Supplemental Information
Beg. Cash$70,971$210,518$60,063$24,521
End Cash$50,817$70,971$210,518$60,063
Free Cash Flow$12,985-$59,441-$40,277-$17,616